Complete and Durable Response to Combined Chemo/Radiation Therapy in
CDH1
EGFR
TP53
brain metastases
chemotherapy
lung cancer
radiotherapy
tumor mutational burden
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
11 Apr 2019
11 Apr 2019
Historique:
received:
01
03
2019
revised:
02
04
2019
accepted:
09
04
2019
entrez:
14
4
2019
pubmed:
14
4
2019
medline:
14
4
2019
Statut:
epublish
Résumé
Most non-small-cell lung cancer (NSCLC) patients are likely to develop brain metastases during the course of their illness. Currently, no consensus on NSCLC patients' treatment with brain metastasis has been established. Although whole brain radiotherapy prolongs the median survival time of approximately 4 months, a cisplatin-pemetrexed combination may also represent a potential option in the treatment of asymptomatic NSCLC patients with brain metastases. Herein, we report the case of a non-smoker male patient with multiple, large and diffuse brain metastases from an "epidermal growth factor receptor (
Identifiants
pubmed: 30979070
pii: diagnostics9020042
doi: 10.3390/diagnostics9020042
pmc: PMC6627459
pii:
doi:
Types de publication
Case Reports
Langues
eng
Références
J Thorac Oncol. 2008 Apr;3(4):365-73
pubmed: 18379354
J Clin Oncol. 2008 Jul 20;26(21):3543-51
pubmed: 18506025
Lung Cancer. 2010 May;68(2):264-8
pubmed: 19632738
Lancet Oncol. 2012 Mar;13(3):247-55
pubmed: 22341744
Curr Med Chem. 2012;19(12):1751-64
pubmed: 22414083
J Clin Oncol. 2012 Aug 20;30(24):3002-11
pubmed: 22778317
J Neurooncol. 2013 Apr;112(2):247-55
pubmed: 23354655
J Natl Cancer Inst. 2013 May 1;105(9):595-605
pubmed: 23594426
PLoS One. 2013 Oct 29;8(10):e77035
pubmed: 24204729
Mol Cancer Res. 2014 Jan;12(1):3-13
pubmed: 24442106
Nat Rev Clin Oncol. 2014 Apr;11(4):203-22
pubmed: 24569448
Mol Pharmacol. 2014 Jun;85(6):866-76
pubmed: 24627085
Cancer Treat Rev. 2014 Jul;40(6):716-22
pubmed: 24759599
J Chemother. 2015 Aug;27(4):221-6
pubmed: 25735792
Drug Des Devel Ther. 2015 Apr 15;9:2171-8
pubmed: 25931811
Ann Oncol. 2015 Sep;26(9):1877-83
pubmed: 26141208
Radiat Oncol J. 2015 Sep;33(3):207-16
pubmed: 26484304
Clin Chem. 2016 Apr;62(4):647-54
pubmed: 26847218
Cancer Treat Rev. 2016 Apr;45:139-62
pubmed: 27019457
Curr Treat Options Oncol. 2016 May;17(5):25
pubmed: 27085533
J Thorac Oncol. 2016 Oct;11(10):1718-28
pubmed: 27237825
Medicine (Baltimore). 2016 Aug;95(32):e4401
pubmed: 27512852
Int J Mol Sci. 2016 Dec 18;17(12):
pubmed: 27999344
Mol Clin Oncol. 2016 Dec;5(6):705-713
pubmed: 28101350
Lung Cancer. 2017 Sep;111:79-83
pubmed: 28838404
Oncotarget. 2018 Jan 3;9(9):8531-8541
pubmed: 29492214
J Thorac Oncol. 2018 Aug;13(8):1217-1221
pubmed: 29654927
Strahlenther Onkol. 2018 Oct;194(10):873-875
pubmed: 30030581
Medicine (Baltimore). 2019 Jan;98(3):e14110
pubmed: 30653134
Cancer. 1981 Jul 15;48(2):384-94
pubmed: 7237407